Menu Search
Equities

Zhejiang CONBA Pharmaceutical Co Ltd

600572:SHH

Zhejiang CONBA Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)4.59
  • Today's Change-0.18 / -3.77%
  • Shares traded38.22m
  • 1 Year change-14.04%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Zhejiang CONBA Pharmaceutical Co Ltd grew revenues 12.20% from 6.00bn to 6.73bn while net income improved 65.20% from 358.10m to 591.57m.
Gross margin51.47%
Net profit margin8.06%
Operating margin9.87%
Return on assets4.98%
Return on equity7.07%
Return on investment6.93%
More ▼

Cash flow in CNYView more

In 2023, Zhejiang CONBA Pharmaceutical Co Ltd did not generate a significant amount of cash. However, the company earned 898.64m from its operations for a Cash Flow Margin of 13.35%. In addition the company used 289.05m on investing activities and also paid 719.08m in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share2.59
Tangible book value per share2.38
More ▼

Balance sheet in CNYView more

Zhejiang CONBA Pharmaceutical Co Ltd has a Debt to Total Capital ratio of 7.81%, a higher figure than the previous year's 4.33%.
Current ratio1.77
Quick ratio1.24
Total debt/total equity0.086
Total debt/total capital0.0781
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.